Stella Pharma Corporation (TYO:4888)

Japan flag Japan · Delayed Price · Currency is JPY
470.00
+1.00 (0.21%)
At close: Mar 6, 2026
Market Cap16.00B +5.6%
Revenue (ttm)968.00M +199.7%
Net Income-279.00M
EPS-8.20
Shares Out34.03M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume954,700
Average Volume1,748,455
Open468.00
Previous Close469.00
Day's Range445.00 - 482.00
52-Week Range200.00 - 507.00
Beta1.23
RSI65.12
Earnings DateFeb 12, 2026

About Stella Pharma

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 43
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4888
Full Company Profile

Financial Performance

In fiscal year 2025, Stella Pharma's revenue was 961.00 million, an increase of 257.25% compared to the previous year's 269.00 million. Losses were -140.00 million, -81.65% less than in 2024.

Financial Statements